Literature DB >> 19692035

Determinants of success and failure of seromuscular colocystoplasty lined with urothelium.

Ricardo González1, Barbara Ludwikowski, Maya Horst.   

Abstract

PURPOSE: Seromuscular colocystoplasty lined with urothelium is a method of bladder augmentation that avoids incorporating intestinal mucosa into the urinary tract. Others have reported a repeat augmentation rate of 23%. We analyzed the results in 20 patients who underwent the procedure, as performed by one of us (RG), at 3 institutions.
MATERIALS AND METHODS: After receiving institutional review board approval we retrospectively reviewed the charts of all patients operated on since 1998. Preoperative and postoperative bladder capacity at 30 cm H(2)O, expressed as the percent of expected capacity for age using the equation, bladder capacity in ml = (age +1) x 30, as well as prior, concomitant and subsequent bladder or bladder neck procedures, continence and the need for repeat augmentation were recorded.
RESULTS: There were 20 patients, including 7 females, with a mean age at surgery of 9 years and a mean followup of 53 months. All patients had neurogenic bladder dysfunction. An artificial urinary sphincter was implanted at the time of seromuscular colocystoplasty in 10 patients, preoperatively in 6 and postoperatively in 1. A sling was used in 3 females. Patients were divided into 2 groups. The 15 group 1 patients underwent no concomitant procedure in the bladder and the 5 in group 2 underwent creation of a continent channel at seromuscular colocystoplasty. There were no failures of augmentation in group 1, in which bladder capacity increased from 60% of that expected for age to 100%. All patients were continent. Three of the 5 patients in group 2 required repeat augmentation.
CONCLUSIONS: Seromuscular colocystoplasty lined with urothelium has proved to be an effective method to augment the bladder in patients who have an artificial urinary sphincter or who undergo simultaneous artificial urinary sphincter implantation. We do not recommend constructing a continent catheterizable channel at the time of seromuscular colocystoplasty lined with urothelium.

Entities:  

Mesh:

Year:  2009        PMID: 19692035     DOI: 10.1016/j.juro.2009.02.062

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

Review 1.  [Neurogenic bladder function disorders in patients with meningomyelocele: S2k guidelines on diagnostics and therapy].

Authors:  R Stein; C Assion; R Beetz; M Bürst; R Cremer; A Ermert; M Goepel; E Kuwertz-Bröking; B Ludwikowski; T Michael; J Pannek; H Peters; D Rohrmann; I Rübben; A Schröder; R Trollmann; J W Thüroff; W Wagner
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

2.  Opportunities for augmentation cystoplasty revision without additional bowel harvest: "Hourglass" deformity or non-detubularized augment.

Authors:  Joseph J Pariser; Sean P Elliott
Journal:  Can Urol Assoc J       Date:  2018-10-15       Impact factor: 1.862

3.  Transplantation of autologous differentiated urothelium in an experimental model of composite cystoplasty.

Authors:  Alex Turner; Ramnath Subramanian; David F M Thomas; Jennifer Hinley; Syed Khawar Abbas; Jens Stahlschmidt; Jennifer Southgate
Journal:  Eur Urol       Date:  2010-12-22       Impact factor: 20.096

Review 4.  Neurogenic bladder in spinal cord injury patients.

Authors:  Waleed Al Taweel; Raouf Seyam
Journal:  Res Rep Urol       Date:  2015-06-10

Review 5.  Alternatives to conventional enterocystoplasty in children: a critical review of urodynamic outcomes.

Authors:  Ricardo González; Barbara M Ludwikowski
Journal:  Front Pediatr       Date:  2013-10-07       Impact factor: 3.418

6.  Hourglass bladder after ileocystoplasty (case report).

Authors:  Hamdan H Alhazmi
Journal:  Ann Saudi Med       Date:  2015 Sep-Oct       Impact factor: 1.526

Review 7.  The evolution of bladder augmentation: from creating a reservoir to reconstituting an organ.

Authors:  Roman Jednak
Journal:  Front Pediatr       Date:  2014-02-10       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.